Opened: First quarter 2016
Alexion Pharmaceuticals, Inc. is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with severe and life-threatening rare diseases. Patients with these devastating diseases often have no effective treatment options, and they and their families suffer with little hope.
Their first commercial product is Soliris® (eculizumab), the world's first and only approved terminal complement inhibitor. Today, Soliris is approved in nearly 50 countries as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH), and in nearly 40 countries as a treatment for patients with atypical hemolytic uremic syndrome (aHUS). Both PNH and aHUS are life-threatening, ultra-rare diseases that are caused by chronic uncontrolled complement activation
Originally a Yale start-up, the company is returning to New Haven with 300 jobs (and adding 300 new jobs) at a 425,000 s.f. building now under construction in the medical district. The $100+ million investment is the first project at Downtown Crossing, one of the nation's largest highway removal and redevelopment projects.
Visit Alexion's website.